Publication Name	World Journal of Virology
Manuscript ID	121081
DOI	10.5501/wjv.121081
Country	India

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality
Manuscript Source	Invited Manuscript
All Author List	Manish Manrai, Aditya V Pachisia, Atul A Jha, Rajat Shukla, Vivek Hande and Sandeep Thareja
Funding Agency and Grant Number
Corresponding Author	Manish Manrai, AGAF, FRCPE, Professor, Department of Gastroenterology, Command Hospital, Cariappa Road, Lucknow Cantt, Lucknow 226002, Uttar Pradesh, India. manishmanrai75@gmail.com
Key Words	Herpes zoster; Shingles; Recombinant zoster vaccine; Inflammatory bowel disease; Immunosuppression; Janus kinase inhibitors; Vaccination; Postherpetic neuralgia; Crohn’s disease; Ulcerative colitis
Core Tip	Patients with inflammatory bowel disease (IBD) have an elevated risk of herpes zoster due to disease-related immune dysregulation and the widespread use of immunosuppressive therapies, including corticosteroids, thiopurines, biologics, and Janus kinase inhibitors. Major international guidelines now recommend recombinant zoster vaccine for adults aged ≥ 50 years and for younger adults who are or will be immunosuppressed. The recombinant zoster vaccine, a non-live adjuvanted vaccine, is highly effective and safe in immunocompromised populations, including those with IBD. The vaccination uptake among IBD patients remains low, largely due to gaps in awareness, uncertainty regarding timing around therapy, and cost barriers. In the setting of constrained healthcare resources, a risk-stratified approach is more feasible than blanket vaccination.
Citation	Manrai M, Pachisia AV, Jha AA, Shukla R, Hande V, Thareja S. Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality. World J Virol 2026; In press DOI: https://doi.org/10.5501/wjv.121081
PDF	121081-in-press.pdf

Received	2026-03-16 03:43
Peer-Review Started	2026-03-16 03:43
First Decision by Editorial Office Director	2026-04-23 08:30
Return for Revision	2026-04-23 08:30
Revised	2026-06-01 19:28
Publication Fee Transferred
Second Decision by Editor	2026-06-29 02:21
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-06-29 07:54
Articles in Press	2026-06-29 07:54
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2220-3249 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com